MedTrace Logo

First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas

NCT00921037 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-07-13

No results posted yet for this study

Summary

The purpose of this study is to determine whether multiple cutaneous neurofibromas in patients with neurofibromatosis type 1 can be removed with an erbium-YAG-laser.

Conditions

  • Cutaneous Neurofibromas

Interventions

PROCEDURE

Erbium-YAG laser vaporization

spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Wolfgang Happak, Prof. MD · Division of Plastic and Reconstructive Surgery, Surgical Clinic, Medical University of Vienna, Austria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2012-01-31
Completion
2012-11-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00921037 on ClinicalTrials.gov